Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 09 2020
Historique:
received: 27 11 2019
revised: 20 04 2020
accepted: 22 06 2020
pubmed: 27 6 2020
medline: 15 12 2021
entrez: 27 6 2020
Statut: ppublish

Résumé

Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel-Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumor promoting role for HIF-2α, and a tumor suppressor role for HIF-1α. However, few studies have comprehensively examined the clinical relevance of this paradigm. Furthermore, the hypoxia-associated factor (HAF), which regulates the HIFs, has not been comprehensively evaluated in ccRCC. To assess the involvement of HAF/HIFs in ccRCC, we analyzed their relationship to tumor grade/stage/outcome using tissue from 380 patients, and validated these associations using tissue from 72 additional patients and a further 57 patients treated with antiangiogenic therapy for associations with response. Further characterization was performed using single-cell mRNA sequencing (scRNA-seq), RNA- HIF-1α was primarily expressed in tumor-associated macrophages (TAMs), whereas HIF-2α and HAF were expressed primarily in tumor cells. TAM-associated HIF-1α was significantly associated with high tumor grade and increased metastasis and was independently associated with decreased overall survival. Furthermore, elevated TAM HIF-1α was significantly associated with resistance to antiangiogenic therapy. In contrast, high HAF or HIF-2α were associated with low grade, decreased metastasis, and increased overall survival. scRNA-seq, RNA-ISH, and Western blotting confirmed the expression of HIF-1α in M2-polarized CD163-expressing TAMs. These findings highlight a potential role of TAM HIF-1α in ccRCC progression and support the reevaluation of HIF-1α as a therapeutic target and marker of disease progression.

Identifiants

pubmed: 32586940
pii: 1078-0432.CCR-19-3890
doi: 10.1158/1078-0432.CCR-19-3890
pmc: PMC7968518
mid: NIHMS1607780
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
Biomarkers, Tumor 0
HIF1A protein, human 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
endothelial PAS domain-containing protein 1 1B37H0967P

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4970-4982

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA217905
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA224917
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181106
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

©2020 American Association for Cancer Research.

Références

Trends Biochem Sci. 2012 Sep;37(9):364-72
pubmed: 22818162
Cancer Res. 2015 Jan 15;75(2):316-29
pubmed: 25421578
PLoS Biol. 2003 Dec;1(3):E83
pubmed: 14691554
Mol Cancer Ther. 2008 Jan;7(1):90-100
pubmed: 18202012
Blood. 2010 Oct 21;116(16):3039-48
pubmed: 20628150
Mol Cell Biol. 2005 Jul;25(13):5675-86
pubmed: 15964822
Nat Cell Biol. 2016 Apr;18(4):356-65
pubmed: 27027486
Science. 2018 Aug 10;361(6402):594-599
pubmed: 30093597
Cancer Cell. 2016 Oct 10;30(4):515-517
pubmed: 27728802
Nature. 2016 Nov 3;539(7627):107-111
pubmed: 27595393
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
Cancer Cell. 2008 Dec 9;14(6):435-46
pubmed: 19061835
Cancer Cell. 2002 Jun;1(5):459-68
pubmed: 12124175
BMC Cancer. 2015 Aug 08;15:577
pubmed: 26253167
Nature. 2016 Nov 3;539(7627):112-117
pubmed: 27595394
Cancer Res. 2011 Jun 1;71(11):4015-27
pubmed: 21512133
Int J Cancer. 2016 Mar 1;138(5):1058-66
pubmed: 25784597
J Orthop Res. 2014 Aug;32(8):975-80
pubmed: 24677016
Cancer Res. 2010 Dec 15;70(24):10101-11
pubmed: 21159632
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2698-703
pubmed: 24497508
Am J Respir Cell Mol Biol. 2016 Dec;55(6):889-898
pubmed: 27494303
Nat Commun. 2019 Mar 8;10(1):1146
pubmed: 30850588
Int J Cancer. 2012 Dec 15;131(12):2785-94
pubmed: 22505354
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Anticancer Res. 2015 Jan;35(1):433-8
pubmed: 25550584
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
PeerJ. 2017 Nov 17;5:e4065
pubmed: 29158991
Front Oncol. 2018 Jun 11;8:224
pubmed: 29942795
Genes Dev. 2010 Mar 1;24(5):491-501
pubmed: 20194441
Int J Cancer. 2015 Apr 1;136(7):1504-14
pubmed: 25123505
Mol Cell Biol. 2003 Dec;23(24):9361-74
pubmed: 14645546
Eur J Med Chem. 2012 Mar;49:24-40
pubmed: 22305612
Mol Cancer Res. 2019 May;17(5):1220-1232
pubmed: 30705246
PLoS One. 2012;7(1):e31034
pubmed: 22299048
J Mol Med (Berl). 2014 Aug;92(8):825-36
pubmed: 24916472
Eur J Cancer. 2014 May;50(8):1531-40
pubmed: 24565854
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Crit Rev Oncol Hematol. 2017 Mar;111:117-123
pubmed: 28259286
Cancer Discov. 2011 Aug;1(3):222-35
pubmed: 22037472
Mol Cell Biol. 2008 Dec;28(23):7081-95
pubmed: 18838541
Nat Genet. 1994 May;7(1):85-90
pubmed: 7915601
Immunity. 2014 Nov 20;41(5):815-29
pubmed: 25453823
Int J Cancer. 2016 Jul 15;139(2):396-403
pubmed: 26945902

Auteurs

Sophie J Cowman (SJ)

University of Utah, Salt Lake City, Utah.

Daniel G Fuja (DG)

University of Utah, Salt Lake City, Utah.

Xian-De Liu (XD)

U.T. M.D. Anderson Cancer Center, Houston, Texas.

Rebecca S Slack Tidwell (RSS)

U.T. M.D. Anderson Cancer Center, Houston, Texas.

Neelima Kandula (N)

University of Utah, Salt Lake City, Utah.

Deepika Sirohi (D)

University of Utah, Salt Lake City, Utah.

Archana M Agarwal (AM)

University of Utah, Salt Lake City, Utah.

Lyska L Emerson (LL)

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Sheryl R Tripp (SR)

ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah.

Jeffrey S Mohlman (JS)

University of Utah, Salt Lake City, Utah.

Miekan Stonhill (M)

University of Utah, Salt Lake City, Utah.

Guillermina Garcia (G)

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.

Christopher J Conley (CJ)

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Adam A Olalde (AA)

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.

Timothy Sargis (T)

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.

Adela Ramirez-Torres (A)

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.

Jose A Karam (JA)

U.T. M.D. Anderson Cancer Center, Houston, Texas.

Christopher G Wood (CG)

U.T. M.D. Anderson Cancer Center, Houston, Texas.

Kanishka Sircar (K)

U.T. M.D. Anderson Cancer Center, Houston, Texas.

Pheroze Tamboli (P)

U.T. M.D. Anderson Cancer Center, Houston, Texas.

Kenneth Boucher (K)

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Benjamin Maughan (B)

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Benjamin T Spike (BT)

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Thai H Ho (TH)

Mayo Clinic, Scottsdale, Arizona.

Neeraj Agarwal (N)

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Eric Jonasch (E)

U.T. M.D. Anderson Cancer Center, Houston, Texas.

Mei Yee Koh (MY)

University of Utah, Salt Lake City, Utah. mei.koh@utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH